Pub Date : 2025-05-15DOI: 10.1038/s41582-025-01101-x
Ian Fyfe
Single-molecule analysis of amyloid-β antibody binding has shown that lecanemab preferentially binds to small aggregates that form early in Alzheimer disease.
{"title":"Antibodies target different amyloid-β species","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01101-x","DOIUrl":"10.1038/s41582-025-01101-x","url":null,"abstract":"Single-molecule analysis of amyloid-β antibody binding has shown that lecanemab preferentially binds to small aggregates that form early in Alzheimer disease.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 6","pages":"294-294"},"PeriodicalIF":33.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15DOI: 10.1038/s41582-025-01100-y
Ian Fyfe
New work shows that transplantation of dopaminergic progenitor cells derived from human induced pluripotent stem cells is safe and could be effective in Parkinson disease.
新的研究表明，人类诱导多能干细胞衍生的多巴胺能祖细胞移植治疗帕金森病是安全有效的。
{"title":"Stem cells show promise in Parkinson disease","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01100-y","DOIUrl":"10.1038/s41582-025-01100-y","url":null,"abstract":"New work shows that transplantation of dopaminergic progenitor cells derived from human induced pluripotent stem cells is safe and could be effective in Parkinson disease.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 6","pages":"294-294"},"PeriodicalIF":33.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15DOI: 10.1038/s41582-025-01103-9
Ian Fyfe
Measures of glymphatic function could serve as markers of Huntington disease and its progression, new research has shown.
新的研究表明，淋巴功能的测量可以作为亨廷顿病及其进展的标志。
{"title":"Glymphatic flow reduced in Huntington disease","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01103-9","DOIUrl":"10.1038/s41582-025-01103-9","url":null,"abstract":"Measures of glymphatic function could serve as markers of Huntington disease and its progression, new research has shown.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 6","pages":"294-294"},"PeriodicalIF":33.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15DOI: 10.1038/s41582-025-01102-w
Ian Fyfe
A bespoke virtual assistant based on artificial intelligence has outperformed neurologists in the diagnosis of chronic ataxias in a recent study.
在最近的一项研究中，一款基于人工智能的定制虚拟助手在诊断慢性共济失调方面的表现超过了神经科医生。
{"title":"AI aces diagnosis of chronic ataxias","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01102-w","DOIUrl":"10.1038/s41582-025-01102-w","url":null,"abstract":"A bespoke virtual assistant based on artificial intelligence has outperformed neurologists in the diagnosis of chronic ataxias in a recent study.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 6","pages":"294-294"},"PeriodicalIF":33.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14DOI: 10.1038/s41582-025-01092-9
Heather Wood
The Society for Equity Neuroscience (SEQUINS) was founded in 2024 to identify and address global inequities in brain health. Ahead of the inaugural SEQUINS conference in May 2025, we asked Founding President Bruce Ovbiagele about his expectations and aspirations for the conference and for the future of SEQUINS.
{"title":"SEQUINS — a new initiative to address disparities in neurology","authors":"Heather Wood","doi":"10.1038/s41582-025-01092-9","DOIUrl":"10.1038/s41582-025-01092-9","url":null,"abstract":"The Society for Equity Neuroscience (SEQUINS) was founded in 2024 to identify and address global inequities in brain health. Ahead of the inaugural SEQUINS conference in May 2025, we asked Founding President Bruce Ovbiagele about his expectations and aspirations for the conference and for the future of SEQUINS.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 7","pages":"345-346"},"PeriodicalIF":33.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-12DOI: 10.1038/s41582-025-01093-8
Erin E. Sundermann
Growing evidence links menopause to the risk of Alzheimer disease (AD) in women, but the effect of menopause hormone therapy (MHT) on this risk remain unclear. Two new studies illuminate how menopause and MHT influence synaptic health and tau pathology, offering new insights into sex-specific mechanisms and MHT timing considerations in AD risk.
{"title":"Menopause, memory and molecular pathways: growing insights into Alzheimer disease risk in women","authors":"Erin E. Sundermann","doi":"10.1038/s41582-025-01093-8","DOIUrl":"10.1038/s41582-025-01093-8","url":null,"abstract":"Growing evidence links menopause to the risk of Alzheimer disease (AD) in women, but the effect of menopause hormone therapy (MHT) on this risk remain unclear. Two new studies illuminate how menopause and MHT influence synaptic health and tau pathology, offering new insights into sex-specific mechanisms and MHT timing considerations in AD risk.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 7","pages":"349-350"},"PeriodicalIF":33.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143933469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-12DOI: 10.1038/s41582-025-01099-2
Lisa Kiani
A population cohort study has shown that Epstein–Barr virus interacts with genetics to increase the risk of multiple sclerosis.
一项人口队列研究表明，爱泼斯坦-巴尔病毒与基因相互作用，增加了多发性硬化症的风险。
{"title":"Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis","authors":"Lisa Kiani","doi":"10.1038/s41582-025-01099-2","DOIUrl":"10.1038/s41582-025-01099-2","url":null,"abstract":"A population cohort study has shown that Epstein–Barr virus interacts with genetics to increase the risk of multiple sclerosis.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 6","pages":"293-293"},"PeriodicalIF":33.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-12DOI: 10.1038/s41582-025-01090-x
YuHong Fu, Glenda M. Halliday
Biological definitions of neurological diseases are now becoming a reality, although still in the research phase. This development will recategorize neurological diseases, providing objective diagnostics and the promise of therapeutics that target biological mechanisms — similar to the strategy that has proven successful in tumours and other conditions. In this Perspective article, we discuss this development for dementias with dominant Lewy pathology, as the availability of biological assays for this pathology has sparked new interest in a single disease diagnosis for all individuals positive for α-synuclein. On the basis of current evidence, we argue that an α-synuclein assay alone is unlikely to be a specific criterion for a spectrum of clinical syndromes with Lewy pathology or a definitive diagnostic marker for Lewy body dementia. We advocate that one biological assay will not reflect the complex spatiotemporal features of brain pathology. Diverse sequential mechanisms underpin the highly heterogeneous phenotypes and clinicopathological processes of Lewy body dementias. Disease modification, if possible, will be most effective when it targets the early underlying mechanisms, especially those leading to aggressive phenotypes. The development of α-synuclein biomarkers has raised debate as to whether Parkinson disease dementia and dementia with Lewy bodies should fall under a single biological diagnosis. Here the authors discuss the similarities and differences in symptoms, neuropathology and biomarkers of the two dementias, highlighting potential important divergent biological mechanisms.
{"title":"Dementia with Lewy bodies and Parkinson disease dementia — the same or different and is it important?","authors":"YuHong Fu, Glenda M. Halliday","doi":"10.1038/s41582-025-01090-x","DOIUrl":"10.1038/s41582-025-01090-x","url":null,"abstract":"Biological definitions of neurological diseases are now becoming a reality, although still in the research phase. This development will recategorize neurological diseases, providing objective diagnostics and the promise of therapeutics that target biological mechanisms — similar to the strategy that has proven successful in tumours and other conditions. In this Perspective article, we discuss this development for dementias with dominant Lewy pathology, as the availability of biological assays for this pathology has sparked new interest in a single disease diagnosis for all individuals positive for α-synuclein. On the basis of current evidence, we argue that an α-synuclein assay alone is unlikely to be a specific criterion for a spectrum of clinical syndromes with Lewy pathology or a definitive diagnostic marker for Lewy body dementia. We advocate that one biological assay will not reflect the complex spatiotemporal features of brain pathology. Diverse sequential mechanisms underpin the highly heterogeneous phenotypes and clinicopathological processes of Lewy body dementias. Disease modification, if possible, will be most effective when it targets the early underlying mechanisms, especially those leading to aggressive phenotypes. The development of α-synuclein biomarkers has raised debate as to whether Parkinson disease dementia and dementia with Lewy bodies should fall under a single biological diagnosis. Here the authors discuss the similarities and differences in symptoms, neuropathology and biomarkers of the two dementias, highlighting potential important divergent biological mechanisms.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 7","pages":"394-403"},"PeriodicalIF":33.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143933459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-07DOI: 10.1038/s41582-025-01097-4
Michael Aschner
Microplastics have been observed in human brain tissue for the first time, and higher levels were associated with dementia. However, important questions remain about the mechanisms of microplastic accumulation and clearance, the influence of environmental factors such as geographical location, and whether the association with dementia reflects cause or effect.
{"title":"Mind over microplastics — what we still don’t know","authors":"Michael Aschner","doi":"10.1038/s41582-025-01097-4","DOIUrl":"10.1038/s41582-025-01097-4","url":null,"abstract":"Microplastics have been observed in human brain tissue for the first time, and higher levels were associated with dementia. However, important questions remain about the mechanisms of microplastic accumulation and clearance, the influence of environmental factors such as geographical location, and whether the association with dementia reflects cause or effect.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 7","pages":"351-352"},"PeriodicalIF":33.1,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：